Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 51.9 NOK 1.57%
Market Cap: 1.4B NOK

Gross Margin
Photocure ASA

94.2%
Current
94%
Average
49%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.2%
=
Gross Profit
494.7m
/
Revenue
525.4m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
NO
Photocure ASA
OSE:PHO
1.4B NOK
94%
US
Eli Lilly and Co
NYSE:LLY
694B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
365.2B USD
69%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
85%
CH
Roche Holding AG
SIX:ROG
199.3B CHF
73%
CH
Novartis AG
SIX:NOVN
179.1B CHF
75%
UK
AstraZeneca PLC
LSE:AZN
157.6B GBP
82%
US
Merck & Co Inc
NYSE:MRK
200.5B USD
81%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
68%
FR
Sanofi SA
PAR:SAN
113.8B EUR
70%

Photocure ASA
Glance View

Market Cap
1.4B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
72.79 NOK
Undervaluation 29%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.2%
=
Gross Profit
494.7m
/
Revenue
525.4m
What is the Gross Margin of Photocure ASA?

Based on Photocure ASA's most recent financial statements, the company has Gross Margin of 94.2%.

Back to Top